{"nctId":"NCT03911843","briefTitle":"Omega-3 and Vitamin D Supplements in Childhood T1D","startDateStruct":{"date":"2017-01-01","type":"ACTUAL"},"conditions":["Type 1 Diabetes Mellitus"],"count":64,"armGroups":[{"label":"CASES","type":"EXPERIMENTAL","interventionNames":["Drug: omega-3 supplementation","Drug: Vitamin D supplementation"]},{"label":"CONTROLS","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Vitamin D supplementation"]}],"interventions":[{"name":"omega-3 supplementation","otherNames":["Ener Zone Omega 3 RXÂ® Equipe Enervit"]},{"name":"Vitamin D supplementation","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* All T1D patients aged 1-18 years whose disease onset had been in 2017, 2016, 2015, 2014 affering to the Pediatric Diabetology of AOU Novara (Italy)\n* written consents of parents\n* without assumption of omega 3 supplementation before 2017\n\nExclusion Criteria:\n\n* renal cysts\n* sarcoidosis\n* histoplasmosis\n* hyperparathyroidis\n* lymphoma\n* tuberculosis\n* Patients treated with drugs that could affect immunity or glucose metabolism, including corticosteroids, ciclosporin and tacrolimus","healthyVolunteers":true,"sex":"ALL","minimumAge":"1 Year","maximumAge":"18 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Daily Insulin Need (IU/Kg/Day) and Daily Insulin Pre-meal Demand (Pre-meal IU/Kg/Day) at 12 Months","description":"The Daily Insulin Needs (IU/Kg/day), and the Daily Insulin Pre-meal Demand (Pre-meal IU/Kg/day) respectively represent the average total (sum of boluses and basal) and average pre-meal (sum of pre-meal boluses) insulin doses administered in one day to each patient.\n\nThey have been calculated over a week, and were expressed in International Units / Kg of weight, higher values mean a worse outcome.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.49","spread":"0.2"},{"groupId":"OG001","value":"0.63","spread":"0.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.22","spread":"0.1"},{"groupId":"OG001","value":"0.34","spread":"0.1"}]}]}]},{"type":"PRIMARY","title":"HbA1c Percentage","description":"percentage of glycated hemoglobin measured through the high-performance liquid chromatography (HPLC).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.4","spread":"1"},{"groupId":"OG001","value":"7.8","spread":"1"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Insulin Demand Adjusted for HbA1c %(IDAA1c) <9","description":"The IDAA1c (insulin daily dose adjusted for glycosylated hemoglobin percentage) was calculated as HbA1c percentage + average daily insulin dose (IU/kg/24 h) x 4. A score \\<9 meet definition of partial remission and Residual Endogenic Insulin Secretion (REIS). IDAA1c represents a surrogate index of insulin secretion and of metabolic control. In a scale from 5 to 12, higher score mean a worse outcome (e.g. \\<5.5 is expected in a normal individual, \\<9 in an individual in partial remission. See reference).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":22},"commonTop":["persistent diarrhea","transient suppression of TRH","an extension of the aPTT clotting"]}}}